270 related articles for article (PubMed ID: 25633711)
1. Cytomegalovirus-Based Vaccine Expressing a Modified Tumor Antigen Induces Potent Tumor-Specific CD8(+) T-cell Response and Protects Mice from Melanoma.
Qiu Z; Huang H; Grenier JM; Perez OA; Smilowitz HM; Adler B; Khanna KM
Cancer Immunol Res; 2015 May; 3(5):536-46. PubMed ID: 25633711
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus-based cancer vaccines expressing TRP2 induce rejection of melanoma in mice.
Xu G; Smith T; Grey F; Hill AB
Biochem Biophys Res Commun; 2013 Jul; 437(2):287-91. PubMed ID: 23811402
[TBL] [Abstract][Full Text] [Related]
3. Viral-mimicking protein nanoparticle vaccine for eliciting anti-tumor responses.
Molino NM; Neek M; Tucker JA; Nelson EL; Wang SW
Biomaterials; 2016 Apr; 86():83-91. PubMed ID: 26894870
[TBL] [Abstract][Full Text] [Related]
4. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
[TBL] [Abstract][Full Text] [Related]
5. Targeted immunotherapy using reconstituted chaperone complexes of heat shock protein 110 and melanoma-associated antigen gp100.
Wang XY; Chen X; Manjili MH; Repasky E; Henderson R; Subjeck JR
Cancer Res; 2003 May; 63(10):2553-60. PubMed ID: 12750279
[TBL] [Abstract][Full Text] [Related]
6. A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer.
Klyushnenkova EN; Kouiavskaia DV; Parkins CJ; Caposio P; Botto S; Alexander RB; Jarvis MA
J Immunother; 2012 Jun; 35(5):390-9. PubMed ID: 22576344
[TBL] [Abstract][Full Text] [Related]
7. Hydrodynamic limb vein delivery of a xenogeneic DNA cancer vaccine effectively induces antitumor immunity.
Neal ZC; Bates MK; Albertini MR; Herweijer H
Mol Ther; 2007 Feb; 15(2):422-30. PubMed ID: 17235322
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral Infection with Murine Cytomegalovirus Synergizes with PD-L1 Blockade to Clear Melanoma Lesions and Induce Long-term Immunity.
Erkes DA; Xu G; Daskalakis C; Zurbach KA; Wilski NA; Moghbeli T; Hill AB; Snyder CM
Mol Ther; 2016 Aug; 24(8):1444-55. PubMed ID: 27434584
[TBL] [Abstract][Full Text] [Related]
9. Immunization with tumor-derived ER chaperone grp170 elicits tumor-specific CD8+ T-cell responses and reduces pulmonary metastatic disease.
Wang XY; Kazim L; Repasky EA; Subjeck JR
Int J Cancer; 2003 Jun; 105(2):226-31. PubMed ID: 12673684
[TBL] [Abstract][Full Text] [Related]
10. Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge.
Krishnan L; Sad S; Patel GB; Sprott GD
Cancer Res; 2003 May; 63(10):2526-34. PubMed ID: 12750276
[TBL] [Abstract][Full Text] [Related]
11. Demarcated thresholds of tumor-specific CD8 T cells elicited by MCMV-based vaccine vectors provide robust correlates of protection.
Beyranvand Nejad E; Ratts RB; Panagioti E; Meyer C; Oduro JD; Cicin-Sain L; Früh K; van der Burg SH; Arens R
J Immunother Cancer; 2019 Jan; 7(1):25. PubMed ID: 30704520
[TBL] [Abstract][Full Text] [Related]
12. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.
Saenger YM; Li Y; Chiou KC; Chan B; Rizzuto G; Terzulli SL; Merghoub T; Houghton AN; Wolchok JD
Cancer Res; 2008 Dec; 68(23):9884-91. PubMed ID: 19047169
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
14. CD204 suppresses large heat shock protein-facilitated priming of tumor antigen gp100-specific T cells and chaperone vaccine activity against mouse melanoma.
Qian J; Yi H; Guo C; Yu X; Zuo D; Chen X; Kane JM; Repasky EA; Subjeck JR; Wang XY
J Immunol; 2011 Sep; 187(6):2905-14. PubMed ID: 21832164
[TBL] [Abstract][Full Text] [Related]
15. Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma.
Cintolo JA; Datta J; Xu S; Gupta M; Somasundaram R; Czerniecki BJ
Melanoma Res; 2016 Feb; 26(1):1-11. PubMed ID: 26451873
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus vector expressing RAE-1γ induces enhanced anti-tumor capacity of murine CD8
Tršan T; Vuković K; Filipović P; Brizić AL; Lemmermann NAW; Schober K; Busch DH; Britt WJ; Messerle M; Krmpotić A; Jonjić S
Eur J Immunol; 2017 Aug; 47(8):1354-1367. PubMed ID: 28612942
[TBL] [Abstract][Full Text] [Related]
17. Harnessing anti-cytomegalovirus immunity for local immunotherapy against solid tumors.
Çuburu N; Bialkowski L; Pontejo SM; Sethi SK; Bell ATF; Kim R; Thompson CD; Lowy DR; Schiller JT
Proc Natl Acad Sci U S A; 2022 Jun; 119(26):e2116738119. PubMed ID: 35749366
[TBL] [Abstract][Full Text] [Related]
18. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.
Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA
J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823
[TBL] [Abstract][Full Text] [Related]
19. Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy.
Pedersen SR; Sørensen MR; Buus S; Christensen JP; Thomsen AR
J Immunol; 2013 Oct; 191(7):3955-67. PubMed ID: 24018273
[TBL] [Abstract][Full Text] [Related]
20. A study on anti-tumor immunity induced by gene-modified melanoma B16 cells.
Fang L; Wang K; Liu X; Zhang L; Zhang X; Qian L; Lu J; Qian G; Ge S
Oncol Rep; 2008 Jun; 19(6):1589-95. PubMed ID: 18497970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
